Clinical Trial: Long-Term Effects of Semaglutide on Body Composition and Performance in Running

U.S., Oct. 16 -- ClinicalTrials.gov registry received information related to the study (NCT07874932) titled 'Long-Term Effects of Semaglutide on Body Composition and Performance in Running' on Sept. 23.

Brief Summary: Semaglutide, a GLP-1 receptor agonist, has demonstrated significant weight-loss effects in people with obesity and/or type 2 diabetes, but its impact on exercise performance among lean, fit athletes remains unknown. This randomized placebo-controlled parallel intervention study aims to investigate the long-term effects of semaglutide on body composition, muscle mass, volume and function, running economy, and performance as well as on hormonal markers in well-trained male and female runners.

Study Start Date: Oct. 14

Study T...